RT Journal Article
SR Electronic
T1 Effectiveness of BBV152 vaccine against SARS-CoV-2 infections, hospitalizations and deaths among healthcare workers in the setting of high delta variant transmission in New Delhi, India
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.01.22.22269701
DO 10.1101/2022.01.22.22269701
A1 Sumit Malhotra
A1 Mani Kalaivani
A1 Rakesh Lodha
A1 Sameer Bakhshi
A1 Vijay Prakash Mathur
A1 Pooja Gupta
A1 Saurabh Kedia
A1 Jeeva Sankar
A1 Parmeshwar Kumar
A1 Arvind Kumar
A1 Vineet Ahuja
A1 Subrata Sinha
A1 Randeep Guleria
YR 2022
UL http://medrxiv.org/content/early/2022/01/24/2022.01.22.22269701.abstract
AB Background Delta variant transmission resulted in surge of SARS CoV-2 cases in New Delhi, India during the early half of year 2021. Health Care Workers (HCWs) received vaccines on priority for prevention of infection. Real life effectiveness of BBV152 vaccine against severe disease including hospitalization and death was not known.Objective To estimate effectiveness of BBV152 vaccine among HCWs against SARS CoV-2 infection, hospitalization or deathDesign Observational studySetting a multi -speciality tertiary care public funded hospital in New Delhi, India.Participants 12,237 HCWsInterventions BBV152 vaccine (Covaxin, Bharat Biotech limited, Hyderabad, India); whole virion inactivated vaccine; two doses four weeks apartMeasurements vaccine effectiveness after receipt of two doses of BBV152 protecting against any SARS CoV-2 infection, symptomatic infections or hospitalizations or deaths, and hospitalizations or deaths.Results The mean age of HCWs was 36(±11) years, 66% were men and 16% had comorbidity. After adjusting for potential covariates viz age, sex, health worker type category, body mass index, and comorbidity, the vaccine effectiveness (95% Confidence Interval) in fully vaccinated HCWs and ≥14 days elapsed after the receipt of second dose was 44% (37 to 51, p<0.001) against symptomatic infection, hospitalization or death due to SARS CoV-2, and 61% (37 to 76, p<0.001) against hospitalization or death, respectively.Conclusions BBV152 vaccine with complete two doses offer a modest response to SARS CoV-2 infection in real life situations against a backdrop of high delta variant community transmission. Efforts in maximizing receipt of full vaccines should be invested for HCWs, who are at higher occupational risk for infection.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of All India Institute of Medical Sciences, New Delhi gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript